ZEISS Vision Care US Names Healthcare Industry Veteran Gary Rosenblum as President and Chief Executive Officer
Most Recently Serving as President for Oticon, a Division of Demant, Rosenblum Brings 30+ Years of Experience in Medical Technology and Consumer Healthcare to ZEISS
HEBRON, Ky., June 23, 2025--(BUSINESS WIRE)--ZEISS Vision Care, one of the world's leading manufacturers of eyeglass lenses and ophthalmic instruments, announced today that Gary Rosenblum has been named President and Chief Executive Officer of ZEISS Vision Care US, effective June 16, 2025. Rosenblum brings relevant senior leadership experience at Demant, Johnson & Johnson, Abbott and Pfizer to his new role. He succeeds Jens Boy, who has spent more than a decade driving the ZEISS Vision Care business in North America, and will depart the company in pursuit of new opportunities on June 30, 2025.
Rosenblum joins ZEISS following more than eight years at Oticon, a division of Demant, where he served as President for US Hearing Aids and led efforts to bring the company's life-changing hearing solutions to Americans with mild-to-severe hearing loss. Under his leadership, Oticon achieved outstanding results in terms of growing market share and increasing revenue, driven by new approaches in sales, talent development and transformation. Before that, Rosenblum led the Enterprise Customer Team at Johnson & Johnson, working with the largest hospital systems on the West Coast. He's also served as Director, Global Strategic Marketing at Abbott, leading the charge in the worldwide commercialization of the company's Diabetes Care portfolio.
"Gary's hands-on experience in highly relevant healthcare roles and his proven track record of success make him an excellent fit to join the ZEISS Vision Care team," said Sven Hermann, CEO ZEISS Consumer Markets. "With Gary at the helm, I am confident we will continue our positive momentum and maintain ZEISS' leadership in the US market. I am incredibly grateful for the role Jens played in transforming ZEISS Vision Care in North America over the past ten years and wish him the best in his future endeavors."
In his role as president and CEO, Rosenblum will focus on growing ZEISS Vision Care US, both in terms of the core business and future opportunities. Driven by a commitment to protect and improve eye health, he is passionate about continuing the legacy of innovation that has guided ZEISS for more than 179 years.
"I am thrilled to join ZEISS Vision Care and continue to build on the company's mission of delivering industry-leading optical innovations to eyecare professionals and millions of Americans," said Rosenblum. "I am already impressed with our incredible team in the US and their commitment to excellence. I'd like to thank Jens for his support with this transition and look forward to continuing his record of success for the company."
About ZEISS
ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the previous fiscal year, the ZEISS Group generated annual revenue totaling 10 billion euros in its four segments Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology and Consumer Markets (status: 30 September 2023).
For its customers, ZEISS develops, produces and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses and binoculars.
With a portfolio aligned with future growth areas like digitalization, healthcare and Smart Production and a strong brand, ZEISS is shaping the future of technology and constantly advancing the world of optics and related fields with its solutions. The company's significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS' technology and market leadership. ZEISS invests 15 percent of its revenue in research and development – this high level of expenditure has a long tradition at ZEISS and is also an investment in the future.
With over 43,000 employees, ZEISS is active globally in almost 50 countries with around 30 production sites, 60 sales and service companies and 27 research and development facilities (status: 30 September 2023). Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany. The Carl Zeiss Foundation, one of the largest foundations in Germany committed to the promotion of science, is the sole owner of the holding company, Carl Zeiss AG.
Further information at www.zeiss.com
ZEISS Vision Care
ZEISS Vision Care is one of the world's leading manufacturers of eyeglass lenses and ophthalmic instruments. The unit is allocated to the Consumer Markets segment and develops and produces offerings for the entire eyeglass value chain that are distributed globally under the ZEISS brand.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250623187939/en/
Contacts
Press contact Allison for ZEISS Vision CareRebecca BuddinghPhone: +1 619 207 8007E-Mail: rebecca.buddingh@allisonworldwide.com
www.zeiss.com/newsroom www.zeiss.com/vision-news
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
VIG Is a Popular Dividend ETF for Passive Income. But Is It the Best?
With a 1.8% yield, the Vanguard Dividend Appreciation ETF isn't the highest-paying dividend ETF. Instead of focusing on stocks with high yields, it focuses on those with extended track records of dividend increases. It could be a great ETF for investors who are more concerned with building their future income streams. 10 stocks we like better than Vanguard Dividend Appreciation ETF › The Vanguard Dividend Appreciation ETF (NYSEMKT: VIG), also commonly referred to simply by its ticker symbol, VIG, is an index fund that holds a portfolio of more than 330 dividend-paying stocks. But with dozens of excellent exchange-traded funds (ETFs) focused on dividend stocks to choose from, is this one the right fit for you? Let's take a closer look at the Vanguard Dividend Appreciation ETF and which types of investors it could be the best dividend stock ETF for. The Vanguard Dividend Appreciation ETF tracks the S&P U.S. Dividend Growers index, which includes only stocks with established track records of raising their dividends every year. Unlike some of the other dividend-focused ETFs offered by Vanguard, stocks don't necessarily need to have above-average dividend yields to be included -- just a dividend growth streak of at least 10 straight years. In part for this reason, the ETF has a 1.8% yield. That's more than you'd get from an S&P 500 index fund, but it isn't close to what most "high dividend" ETFs offer. However, it's important to realize that this ETF isn't about creating a large stream of income immediately. In fact, the index that it tracks excludes the highest-yielding 25% of stocks that would otherwise meet its criteria. Though that might seem counterintuitive, there's a logical reason why: Often, a particularly high dividend yield is the result of a plunging stock price. Given that many noteworthy stock declines are triggered by bad news for the underlying business, and that such troubles can make it harder for a company to pay and raise dividends, foregoing the highest-yielding options in the near term can be a smart strategy for achieving reliable payout growth over the long term. The idea is that this fund holds stocks that will be paying significantly more in dividends 10 years from now, 20 years from now, and so on. Like most Vanguard ETFs, the Dividend Appreciation ETF is a low-cost investment vehicle. It has a rock-bottom 0.05% expense ratio, which means that for every $10,000 in invested assets, your annual fee expense will be just $5. (To be clear, this isn't a fee you have to pay -- it will simply be reflected in the fund's performance over time.) As of the latest update, the Vanguard Dividend Appreciation ETF owned 337 stocks, and it's a weighted index, so some stocks make up significantly more of the portfolio than others. Top holdings include Broadcom, Microsoft, Apple, Eli Lilly, and JPMorgan Chase. One of the most interesting features of this ETF is that because it doesn't require above-average dividend yields, it includes a lot of high-growth companies that many dividend ETFs exclude. For example, Broadcom -- the largest holding in the fund -- has a dividend yield of just 1% at its current share price. However, that tech company has grown its payouts at a double-digit percentage pace and has increased them for 14 consecutive years. Because it has more growth stock exposure than most dividend ETFs, the Vanguard Dividend Appreciation ETF has the potential to deliver stronger total returns. There's no such thing as an ideal dividend ETF for everyone -- that's why there are dozens of them to choose from. The Vanguard Dividend Appreciation ETF could be an especially great choice for investors who want dividend income in their portfolios but are more concerned with how much they'll be getting paid in the future than the current yields of their stocks. In a nutshell, if you're 70 years old and relying on your portfolio for income today, or if you're preparing to retire within the next few years, the Vanguard Dividend Appreciation ETF might not be a great fit for you. On the other hand, if you're still a decade or more away from retirement, it could be an excellent ETF to help you build an income stream for the future without sacrificing growth potential. Before you buy stock in Vanguard Dividend Appreciation ETF, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Vanguard Dividend Appreciation ETF wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 JPMorgan Chase is an advertising partner of Motley Fool Money. Matt Frankel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Apple, JPMorgan Chase, Microsoft, and Vanguard Dividend Appreciation ETF. The Motley Fool recommends Broadcom and recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. VIG Is a Popular Dividend ETF for Passive Income. But Is It the Best? was originally published by The Motley Fool Sign in to access your portfolio
Fox News
26 minutes ago
- Fox News
Iran's leadership is ‘worried' about its future, UC Berkeley professor says
All times eastern Fox Business in Depth: Red, White and Blue Collar/Dagen McDowell Maria Bartiromo's Wall Street FOX News Radio Live Channel Coverage
Yahoo
26 minutes ago
- Yahoo
Camden National (NASDAQ:CAC) Will Pay A Dividend Of $0.42
The board of Camden National Corporation (NASDAQ:CAC) has announced that it will pay a dividend of $0.42 per share on the 31st of July. This makes the dividend yield 4.1%, which will augment investor returns quite nicely. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. We like to see robust dividend yields, but that doesn't matter if the payment isn't sustainable. Having distributed dividends for at least 10 years, Camden National has a long history of paying out a part of its earnings to shareholders. Past distributions do not necessarily guarantee future ones, but Camden National's payout ratio of 54% is a good sign as this means that earnings decently cover dividends. The next year is set to see EPS grow by 27.9%. Assuming the dividend continues along recent trends, we think the future payout ratio could be 51% by next year, which is in a pretty sustainable range. Check out our latest analysis for Camden National Even over a long history of paying dividends, the company's distributions have been remarkably stable. The annual payment during the last 10 years was $0.72 in 2015, and the most recent fiscal year payment was $1.68. This works out to be a compound annual growth rate (CAGR) of approximately 8.8% a year over that time. Dividends have grown at a reasonable rate over this period, and without any major cuts in the payment over time, we think this is an attractive combination as it provides a nice boost to shareholder returns. Some investors will be chomping at the bit to buy some of the company's stock based on its dividend history. Unfortunately things aren't as good as they seem. Over the past five years, it looks as though Camden National's EPS has declined at around 5.4% a year. If earnings continue declining, the company may have to make the difficult choice of reducing the dividend or even stopping it completely - the opposite of dividend growth. Earnings are forecast to grow over the next 12 months and if that happens we could still be a little bit cautious until it becomes a pattern. An additional note is that the company has been raising capital by issuing stock equal to 16% of shares outstanding in the last 12 months. Regularly doing this can be detrimental - it's hard to grow dividends per share when new shares are regularly being created. Overall, we think Camden National is a solid choice as a dividend stock, even though the dividend wasn't raised this year. The earnings coverage is acceptable for now, but with earnings on the decline we would definitely keep an eye on the payout ratio. This looks like it could be a good dividend stock going forward, but we would note that the payout ratio has been at higher levels in the past so it could happen again. Investors generally tend to favour companies with a consistent, stable dividend policy as opposed to those operating an irregular one. Meanwhile, despite the importance of dividend payments, they are not the only factors our readers should know when assessing a company. Taking the debate a bit further, we've identified 1 warning sign for Camden National that investors need to be conscious of moving forward. Is Camden National not quite the opportunity you were looking for? Why not check out our selection of top dividend stocks. — Investing narratives with Fair Values A case for TSXV:USA to reach USD $5.00 - $9.00 (CAD $7.30–$12.29) by 2029. By Agricola – Community Contributor Fair Value Estimated: CA$12.29 · 0.9% Overvalued DLocal's Future Growth Fueled by 35% Revenue and Profit Margin Boosts By WynnLevi – Community Contributor Fair Value Estimated: $195.39 · 0.9% Overvalued Historically Cheap, but the Margin of Safety Is Still Thin By Mandelman – Community Contributor Fair Value Estimated: SEK232.58 · 0.1% Overvalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
